Actinogen Medical Limited
Actinogen Medical Limited is a clinical-stage biotechnology company focused on developing innovative therapies for neurological and neurodegenerative diseases. The company’s lead asset, Xanamem®, is designed to target cognitive impairment associated with conditions such as Alzheimer’s disease and major depressive disorder. Actinogen Medical leverages advanced research in cortisol modulation to address unmet medical needs in central nervous system disorders. With a commitment to rigorous clinical development and scientific excellence, Actinogen Medical aims to deliver effective, safe, and accessible treatments that improve patient outcomes. The company collaborates with global partners and maintains a strong pipeline of potential therapies to address significant challenges in brain health.
